Capricor Therapeutics
CAPR
30 hedge funds and large institutions have $10M invested in Capricor Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
3% less funds holding
Funds holding: 31 → 30 (-1)
4.6% less ownership
Funds ownership: 15.42% → 10.82% (-4.6%)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
45% less capital invested
Capital invested by funds: $18.1M → $10M (-$8.07M)
46% less call options, than puts
Call options by funds: $1.18M | Put options by funds: $2.21M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$251K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$217K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$204K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$191K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$130K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$5.98M |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$251K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$194K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$85K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$71.6K |
CAPR Hedge Fund Activity: Q3 2021 in Review
30 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q3 2021, worth a combined $10M — down 45% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CAPR and 6 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 9 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $251K. The largest seller was Oracle Investment Management, exiting entirely with an estimated $5.98M sold.
- 30 institutional investors held Capricor Therapeutics (CAPR) as of Q3 2021, down from 31 in Q2 2021.
- Funds reported $10M of Capricor Therapeutics stock for Q3 2021, down 45% quarter-over-quarter.
- 6 funds opened new Capricor Therapeutics positions in Q3 2021 and 7 closed out, a net change of -1 holder.
- The largest Capricor Therapeutics buyer in Q3 2021 was Virtu Financial, an estimated $251K added.
- The largest Capricor Therapeutics seller in Q3 2021 was Oracle Investment Management, an estimated $5.98M sold.
Based on aggregated 13F filings for Q3 2021.